Amneal announced the launch of Aripiprazole Oral Solution, the generic version of Otsuka’s Abilify Oral Solution.

Aripiprazole is an atypical antipsychotic indicated for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and treatment of Tourette’s disorder. Its mechanism of action in schizophrenia or bipolar mania is unknown but its efficacy may be mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors.

RELATED: New Antipsychotic Agent Approved for MDD, Schizophrenia

Aripiprazole Oral Solution is available as a 1mg/mL strength in 150mL (5 floz) bottles.

For more information call (877) 835-5472 or visit